A Thai woman, with no family history of bleeding disorders, presented with excessive bleeding after minor trauma and tooth extraction. The screening coagulogram revealed prolonged activated partial thromboplastin time and prothrombin time. The specific-factor assay confirmed the diagnosis of combined factor V and factor VIII deficiency (F5F8D). Her plasma levels of factor V and factor VIII were 10% and 12.5% respectively. The medications and blood product treatment to prevent bleeding from invasive procedure included 1-deamino-8-d-arginine vasopressin, cryoprecipitate, factor VIII concentrate, fresh frozen plasma and antifibrinolytic agent.Gene analysis of the proband identified two LMAN1 gene mutations; one of which is 823-1 G fi C, a novel splice acceptor site mutation that is inherited from her father, the other is 1366 C fi T, a nonsense mutation that is inherited from her mother. Thus, the compound heterozygote of these two mutations in LMAN1 cause combined F5F8D.
Introduction
Combined factor V and factor VIII deficiency (F5F8D) is a rare autosomal recessive bleeding disorder first described by Oeri et al. [1] . To date more than 100 recognized cases have been reported, usually in the context of consanguineous marriage [2] [3] [4] [5] [6] . The estimated prevalence of the disease is about 1:100 000.
The presentation is mild to moderate bleeding symptoms such as easy bruising, menorrhagia, epistaxis, gum bleeding, muscle bleeding and bleeding after surgery or tooth extraction. The reported plasma level of both factors ranges between 5% and 30% and the successful treatments in order to prevent bleeding from surgery include administration of 1-deamino-8-d-arginine vasopressin (DDAVP) and plasma transfusion [7, 8] .
Previous mechanisms proposed for this condition included deficiency of a protein C inhibitor [9] and coinheritance of both factor VIII and factor V deficiency [10] . In 1997, Nichols et al. [11] used homozygosity mapping to identify a 2.5 cM locus on chromosome 18 that was tightly linked to the gene for F5F8D. Shortly after that, the recombinant interval at chromosome 18q21 was matched to the gene LMAN1 (previously identified as ERGIC-53), a protein of the endoplasmic reticulum (ER)-Golgi intermediate compartment with previously unknown function [12] [13] [14] . At present, LMAN1 mutations are identified in 74% of the patients [15, 16] . Until 2003, Zhang et al. [17] described mutations in a second gene, called multiple combined factor deficiency 2 (MCFD2) on chromosome 2, which forms the complex to the ERGIC through a direct, calcium-dependent interaction with LMAN1. The mutation found on MCFD2 can explain this disease in almost all of the remaining patients.
We report the clinical presentations and the identification of LMAN1 mutations in a non-consanguineous, Thai ethnic background patient who was diagnosed with F5F8D.
Methods
After obtaining the informed consent, blood samples were collected by standard double syringe technique from an antecubital vein into evacuated tubes containing EDTA and sodium citrate for complete blood count and coagulation tests, respectively. The samples were centrifuged at 1,600 g for 15 min within 2 h after collection. Then, the plasma was frozen at )70°C until further study. Coagulation tests included activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT). Factor VIII and factor V clotting activities (factor VIII:C and factor V:C) were performed using the one stage method, based on the APTT and PT, respectively, with human lyophilized factor deficient plasma obtained from Instrumentation Laboratory, USA.
The DNA fragments containing coding exons and exon-intron junctions of MCFD2 and LMAN1 genes from the proband and family members were amplified by polymerase chain reaction (PCR) and sequenced as described [16, 17] .
Results
A 25-year-old Thai woman was born after an uneventful pregnancy with no family history of bleeding disorders or consanguineous marriage. She was found with superficial bruising a few times during her toddler period and a traumatic bleeding episode in her left eye, which subsequently caused her vision loss of that eye at the age of 2. She also had a history of prolonged bleeding after tooth extraction at the age of 10 and was referred to our centre when she was 11 years old for the investigation of the aetiology of bleeding and a heart murmur problem.
Clinical examination showed a few bruises on her forearm, an atrophic left eye, dental caries and mild cardiomegaly with systolic ejection murmur grade 4/6 and early diastolic murmur grade 2/6 at the left upper sternal border.
At that time, her laboratory findings revealed a normal complete blood count, normal liver profile and normal blood chemistry. The coagulogram showed a prolonged APTT 68 s [normal range (N) 32-38 s] and PT of 18.5 s (N 11.5-14.5 s) but normal TT of 10 s (N 9-12 s). Coagulation factors showed fibrinogen 292 mg dL )1 , prothrombin 120%, factor VII clotting activity 63%, factor IX clotting activity 90%, factor X clotting activity 62%, factor V clotting activity 10%, factor VIII clotting activity 12.5%, factor VIII antigen 8% and von Willebrand factor antigen 80%. The bleeding time was 6 min and platelet aggregation induced by ADP, adrenalin, collagen and ristocetin was normal. Thus, the diagnosis of F5F8D was made.
The results of the chest X-ray, electrocardiogram and 2D-echocardiography all supported the diagnosis of subaortic ventricular septal defect and aortic valve insufficiency.
During the hospitalized period, a clinical trial of 0.3 lg kg )1 of DDAVP via intravenous route was conducted. The factor VIII:C peak response increased from 10% to 70% at 30 min, 28% at 12 h and 18% at 24 h; however, factor V:C was not changed. As fresh frozen plasma (FFP) had been used in order to increase factor V:C, the dose of 20 mL kg )1 was able to increase factor V:C from 10% to 25%.
For tooth extraction, oral tranexamic acid was given. The haemostasis was achieved by giving 20 mL kg )1 of FFP and 0.3 lg kg )1 of DDAVP for raising factor V:C and factor VIII:C, respectively, prior to procedure. The celluloid splint was applied as a local haemostatic measure immediately after tooth extraction. Subsequently, FFP, at 10 mL kg )1 , and DDAVP were given every 12 h for three times. Before removal of the splint, 20 mL kg )1 of FFP and DDAVP were given. No excessive bleeding occurred.
For open heart surgical correction, factor VIII concentrate had been used at 50 l kg )1 in order to raise the level to 100%. The level was maintained with continuous infusion of factor VIII concentrate. During surgery and the postoperative period, the rate of infusion was adjusted by maintaining the plasma level at about 80-100% on days 1-3. The FFP at 10 mL kg )1 , was infused within 1 h before operation and 10 mL kg )1 during operation to maintain the haemostatic level of factor V. After surgery FFP, at 10 mL kg )1 , was given every 8 h on days 1-3. Subsequently both factor VIII concentrate and FFP infusions were gradually decreased after day 4 postoperatively. On days 4-8, the factor VIII levels were maintained at 40-50% and FFP, at 10 mL kg )1 , was given every 12 h until the sutured material stitches were removed.
To identify the mutation causing F5F8D in this patient, DNA was amplified by PCR using gene analysis of the proband. The smaller MCFD2 gene was first sequenced. No mutations were identified.
We then sequenced the LMAN1 gene and identified two mutations. One is 823-1G fi C, a splice site mutation at the exon 8 splice acceptor site and the other is 1366C fi T, a nonsense mutation in exon 11 that causes a change from a codon for arginine (CGA) to a stop codon (TGA).
Family pedigree is shown in Fig. 1 . Her family members, numbers II.2, II.5, II.6, III.1, III.5, III.7, IV.1 and IV.4, have no history of bleeding disorders. The coagulation screening revealed normal APTT, PT and TT. Their factor V and factor VIII levels were in the normal range. The gene analyses for family members are as follows: numbers II.6, III.1, III.5 and III.7 show heterozygous for the 1366C fi T mutation while number II.5 showing heterozygous for the 823-1G fi C mutation. Family numbers III.3 and III.9 succumbed to stomach cancer at age 38 and sudden death because of an unidentified cause at age 26 respectively. The details are shown in Table 1 and Fig. 1 .
Discussion
Congenital F5F8D is a rare bleeding disorder, usually found in families with a history of consanguineous marriage [2] [3] [4] [5] [6] . The affected families have been reported from many places such as the Middle East, North America, Europe and the Far East. The highest frequency of this disorder is found in Jews of Sephardim and Middle Eastern origin living in Israel. To our knowledge, this paper describes the only reported case of combined F5F8D in Thailand. The presentation of this disorder is usually a mild to moderate bleeding tendency, which may require treatment when patients are undergoing a surgical procedure. Our patient has had a history of easy bruising and bleeding after trauma and tooth extraction. However, no history of menorrhagia, epistaxis or gastrointestinal bleeding was found. The diagnosis for this disorder can be made by screening coagulogram and factor assay. The range of factor V and factor VIII levels are between 5% and 30%. For our patient, her factors V and VIII levels are at 10% and 12.5% respectively. Treatment for the bleeding episodes consists of DDAVP, which can increase the factor VIII level up to three times [18] . The FFP at a dose of 20 mL kg
can increase factor V level to 30% [19] . An antifibrinolytic agent is also useful to prevent clot lysis especially at the mucosal surface such as tooth extraction or tonsillectomy [7, 8] . Our patient showed a good response to initial DDAVP administration, which resulted in a sevenfold increase in factor VIII:C. For factor V:C, the haemostatic level was raised to 25-30% by giving a loading dose of FFP 20 mL kg )1 . We found that the patient had compound heterozygous mutations in the LMAN1 gene which includes two mutations. One is 823-1G fi C, a mutation that destroys the essential acceptor consensus (AG) of exon 8 and is expected to result in a null allele. This is the first reported splice acceptor site mutation in LMAN1. The most likely consequence of this mutation is the skipping in the exon 8 and frameshift in exon 9. A less likely scenario is the use of a cryptic splice site which results in the disruption of the open reading frame of LMAN1 mRNA. The other mutation is 1366C fi T, a nonsense mutation in exon 11 that causes a change from a CGA to a TGA (R456X). The same mutation had been reported previously [15] . Her father is heterozygote for the 823-1G fi C mutation and her mother is heterozygote for the 1366C fi T mutation. Therefore the proband is a compound heterozygote that has inherited two different null mutations from her parents. Most of the previously described patients have homozygous mutations because of consanguineous marriage [15, 16] . This report describes a native Thai family with no consanguinity. Previous studies have demonstrated that LMAN1 is required for efficient secretion of factor VIII and factor V and that this is mediated by oligosaccharide structures within their respective B domains [11] [12] [13] [14] [15] [16] [17] . In the absence of LMAN1, MCFD2 is also not retained with the ER or intermediate compartment. This patient has two null mutations which predicts a loss in the function of LMAN1 and could explain her clinical presentation and laboratory findings. Family members who have the heterozygous mutations do not have any history of bleeding tendency and all coagulation test results are normal suggesting that only low level of LMAN1 expression is required for efficient factor V and factor VIII expression and is consistent with previous reports [15, 16] .
